Previsão
O preço-alvo médio dos analistas é € 118,39 (+1,54%). A mediana é € 123,03 (+5,52%).
| Comprar |
2 |
| Manter |
12 |
| Vender |
0 |
Discussões na comunidade
Ainda não há nenhuma discussão sobre este ativo.
Iniciar discussãoNotícias Ir para o feed de notícias
Apogee Therapeutics reaches record high at $134.89
Apogee Therapeutics' stock reached a record high of $134.89, representing a year-to-date gain of 256.92%. InvestingPro notes the stock may appear overvalued at this level and that its fair-value estimate is substantially lower. Apogee has more cash than debt but was unprofitable over the past twelve months. Shareholders approved AbbVie's acquisition, which values the company at $10.9 billion ($135.11 per share) and prompted analyst downgrades and adjusted price targets. » Mais em de.investing.com
Apogee Therapeutics reaches record high at $134.47 ahead of takeover by AbbVie
Apogee Therapeutics shares rose to an all-time high of $134.47 and show a year-to-date return of around 270% with a market capitalization of $10.08 billion. AbbVie announced an acquisition agreement at $135.11 per share, valuing Apogee at about $10.9 billion, while InvestingPro and RSI indicators point to overvaluation and overbought conditions. After the announcement, Mizuho and UBS downgraded the stock from buy to neutral, while RBC raised its price target to $97; Apogee also closed R&D agreements with Paragon Therapeutics and appointed new directors. » Mais em de.investing.com
Apogee Therapeutics sold by Baron Capital after AbbVie agrees $135.11-per-share buyout
Baron Health Care Fund sold its position in Apogee Therapeutics following AbbVie's announced acquisition of Apogee for $135.11 per share, a 49.5% premium to the prior close. The fund cited Apogee as a key contributor to its biotechnology stock selection during Q2 and reported overall quarterly gains. Apogee shares have risen sharply over the past year and the deal values the company at roughly $10.11 billion. » Mais em finance.yahoo.com
Apogee Therapeutics reaches record high of $134.34
Shares of Apogee Therapeutics rose to an all-time high of $134.34, about 243% above last year; market capitalization is roughly $10.05 billion. AbbVie announced a takeover agreement at $135.11 per share, valuing the company at about $10.9 billion, after which analysts at Mizuho and UBS downgraded the stock to "Neutral" and cited price targets around $135. Additional developments: a partnership with Paragon Therapeutics to develop an IL-31R antibody, an RBC price target of $97, and the move of zumilokibart into phase III trials. » Mais em de.investing.com
Apogee Therapeutics reaches record high of $133.88 after takeover agreement with AbbVie
Apogee Therapeutics' stock rose to a record high of $133.88, bringing market capitalization to about $10.02 billion. InvestingPro rates the stock as overvalued versus its fair value and notes an overbought RSI, despite strong performance (+250% over the past year). AbbVie announced a definitive takeover agreement at $135.11 per share (around $10.9 billion), after which several analysts downgraded their ratings to neutral and set price targets near $135. Additionally, Apogee announced collaboration agreements with Paragon Therapeutics to develop antibodies against the interleukin-31 receptor, and confirmed board elections and approved shareholder proposals. » Mais em de.investing.com
Dados financeiros
No último trimestre, Apogee Therapeutics registou receitas de € 0 e um ganho líquido de -€ 75,23 mi
| (EUR) | junho de 2026 | YoY |
|---|---|---|
| Receitas | 0 | - |
| Ganho bruto | 0 | - |
| Ganho líquido | -75,23 mi | 34,15% |
| EBITDA | -73,42 mi | 31,86% |
Dados fundamentais
| Métrica | Valor |
|---|---|
Capitalização bolsista | € 7,66 bi |
Número de ações | 62,2 mi |
Máximo/mínimo de 52 semanas | € 123,11 - € 32,25 |
| Dividendos | Não |
Beta | 0,34 |
PER (PE Ratio) | -31,12 |
PEG (PEG Ratio) | 6,57 |
P/VC (PB Ratio) | 8,53 |
P/V (PS Ratio) | 0,00 |
Perfil da empresa
A Apogee Therapeutics, Inc., através da sua subsidiária, opera como uma empresa de biotecnologia que desenvolve biológicos para o tratamento de dermatite atópica (DA), doença pulmonar obstrutiva crónica (DPOC) e outras indicações inflamatórias e imunológicas relacionadas. A empresa desenvolve principalmente o APG777, um anticorpo monoclonal (mAb) de semivida prolongada de administração subcutânea (SQ) para a DA; e o APG808, um mAb de semivida prolongada SQ para a DPOC. Os seus programas em fases mais iniciais incluem o APG990, um mAb de semivida prolongada SQ para o tratamento da DA; e o APG222, anticorpos de semivida prolongada SQ para a DA. A empresa foi fundada em 2022 e tem sede em Waltham, Massachusetts.
| Nome | Apogee Therapeutics |
| CEO | Michael Thomas Henderson |
| Sede | Waltham,
ma EUA |
| Site | |
| Indústria | Produtos alimentares |
| Entrada em bolsa | 14/07/2023 |
| Colaboradores | 261 |
Análise aprofundada
Símbolos de ticker
| Bolsa | Símbolo |
|---|---|
NASDAQ | APGE |